BioVie KOL Event on NE3107: Data in Context Ahead of Upcoming Phase 3 Results in Alzheimer’s Disease
About The Event
Join us for a virtual KOL event focusing on BioVie’s lead product candidate, NE3107, currently in a potentially pivotal Phase 3 study in patients with mild to moderate Alzheimer’s disease with expected topline data readout in the fourth quarter of 2023. The company’s leadership team and Key Opinion Leader (KOL) Steven E. Arnold, MD (Harvard Medical School; Massachusetts General Hospital) will discuss the totality of NE3107 data generated to date including:
- Overview of results observed in the NE3107 Phase 2 exploratory biomarker study.
- The role of neuroinflammation and insulin resistance in Alzheimer’s Disease pathology.
- The potential for NE3107 to have an active epigenetic effect associated with improvements in inflammation, insulin signaling, and other critical biological processes in a manner that is significantly correlated to improvements in cognition.
A live question and answer session will follow the formal presentations.